Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial,European Journal of Heart Failure

当前位置： X-MOL 学术 › Eur. J. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2021-11-28 , DOI: 10.1002/ejhf.2394
Susana Ravassa _{1,

2} , Begoña López _{1,

2} , João Pedro Ferreira ₃ , Nicolas Girerd ₃ , Erwan Bozec ₃ , Pierpaolo Pellicori ₄ , Beatrice Mariottoni ₅ , Franco Cosmi ₅ , Mark Hazebroek ₆ , Job A J Verdonschot ₆ , Joe Cuthbert ₇ , Johannes Petutschnigg ₈ , María U Moreno _{1,

2} , Stephane Heymans ₆ , Jan A Staessen _{9,

10} , Burkert Pieske _{8,

11} , Frank Edelmann ₈ , Andrew L Clark ₇ , John G F Cleland ₄ , Faiez Zannad ₃ , Javier Díez _{1,

2,

12} , Arantxa González _{1,

2} ,

Affiliation

Program of Cardiovascular Diseases, CIMA, Universidad de Navarra and IdiSNA, Pamplona, Spain.
CIBERCV, Carlos III Institute of Health, Madrid, Spain.
Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.
Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.
Department of Cardiology, Cortona Hospital, Arezzo, Italy.
Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands.
Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, UK.
Department of Internal Medicine and Cardiology Campus Virchow Klinikum, Charité University Medicine Berlin and German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
Non-Profit Research Institute Alliance for the Promotion of Preventive Medicine, Mechelen (APPREMED), Mechelen, Belgium.
Biomedical Sciences Group, Faculty of Medicine, University of Leuven, Leuven, Belgium.
Berlin Institute of Health, Berlin, Germany.
Departments of Nephrology and Cardiology, Clínica Universidad de Navarra, Pamplona, Spain.

The HOMAGE randomized trial found that spironolactone reduced left atrial volume index (LAVI), E:A ratio, and a marker of collagen type I synthesis (procollagen type I C-terminal propeptide) in patients at risk of heart failure (HF). Previous trials showed that patients with HF, preserved ejection fraction and low serum collagen type I C-terminal telopeptide to matrix metalloproteinase-1 ratio (CITP:MMP-1), associated with high collagen cross-linking, had less improvement in diastolic function with spironolactone. We evaluated the interaction between serum CITP:MMP-1 and spironolactone on cardiac function in the HOMAGE trial.

中文翻译：

基于生物标志物的胶原交联评估确定有心力衰竭风险的患者更有可能受益于螺内酯对左心房重塑的影响。来自 HOMAGE 临床试验的见解

HOMAGE 随机试验发现，在有心力衰竭 (HF) 风险的患者中，螺内酯可降低左心房容积指数 (LAVI)、E:A 比率和 I 型胶原合成标志物（I 型前胶原 C 末端前肽）。先前的试验表明，与高胶原交联相关的 HF、射血分数保留和血清 I 型胶原 C 端端肽与基质金属蛋白酶-1 比率 (CITP:MMP-1) 较低的患者舒张功能改善较少螺内酯。我们在 HOMAGE 试验中评估了血清 CITP:MMP-1 和螺内酯对心脏功能的相互作用。

更新日期：2021-11-28

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11